Patents Secured for Promising Cannabinoid Pain-patch
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Cannabis Leaf has announced that they have secured the IP rights for Pain Patch, Apotheca Biosciences’ pain alleviation technology.
Apotheca has been developing Pain-Patch using CannaDERME transdermal delivery and state-of-the art smart device technologies for relieving various pains. Apotheca has formulated cannabidiol-based Pain-Patch for proof-of-concept studies. The company has now secured the two patent rights for this novel device which encompasses CannaDERME™ transdermal formulation and Pain-patch medical device technologies.
• Cannabidiol is one of the key cannabinoid constituents of the Hemp Plant. CBD is non-psychoactive and safe compound with a wide range of therapeutic applications, including the treatment of neural disorders and clinical studies have suggested a wide range of possible therapeutic effects of cannabidiol on several conditions.
• The Pain-Patch has transcutaneous cannabinoid penetration technology coupled with thermosensitive nano-emulsion for sustained release of compounds for longer time. The device delivers therapeutic doses to brain via brain stem for whole-body effect.
• The goal of these patches are to produce a pain-patch with a small footprint for easy concealment, a strong formula to counteract the decreased quality of life for individuals who suffer with systemic pain, a long shelf-life and the use of non-toxic and non-abrasive components to create the most comfortable and effective patch on the market using this technology.
• Apotheca is partnering up with pain management physician and opioid addiction centers groups for conducting clinical studies using Pain-Patch for various kinds of chronic pain and addiction.
“We shared our pain-patch with leading pain doctors in the region and they were all excited”; Preliminary studies on pain-patch shows excellent results” said Bobban Subhadra, M.S., Ph.D, Chief Operating Officer of Apotheca. “We are securing the IP rights and partnering with more pain doctors to get their valuable clinical feedback” he added.